CLL1 and CD38 dual-target CAR-T injection / 920th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, AstraZeneca - LARVOL DELTA

Study to Evaluate the Safety and Preliminary Efficacy of CLL1 and CD38 Dual CAR-T in r/r AML (clinicaltrials.gov) - P1 | N=3 | Terminated | Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | N=18 ➔ 3 | Trial completion date: Oct 2026 ➔ Jul 2024 | Recruiting ➔ Terminated | Trial primary completion date: Aug 2026 ➔ Jul 2024; Collaborator's decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD38